OPIOIDIQ: Educational tools for proper opioid use


Brought to you by Collegium Pharmaceutical, Inc.: OpioidIQ offers downloadable tools to help you identify unintentional opioid misuse, enhance patient communication, and optimize treatment management.

OPIOIDIQ: educational tools for proper opioid use

Brought to you by Collegium Pharmaceutical, Inc.

OpioidIQ provides a variety of resources to help you educate your patients on proper opioid use by:

  • Identifying patients at risk Who is at Risk?: Find out which of your patients may be at risk for unintentional misuse
  • Enhancing patient communication Conversation Starter: Initiate a conversation with your patients to identify who may be misusing their medication
  • Empowering patients and caregivers to avoid unintentional misuse Patient FAQ Brochure: Help answer your patients’ frequently asked questions about opioids Caregiver Brochure: Provide important information about opioids that your patients’ caregivers need to know Administration Tracker: Encourages your patients to keep track of how they take their medication Take-back Flashcard: Provides tips for proper disposal of unused or expired medication

To download these tools or to learn more about misuse of opioids, visit OpioidIQ.com

Who we are

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company developing and commercializing products for the treatment of patients suffering from chronic pain and other diseases

Our mission

To provide innovative medications through scientific technology

Our vision

We believe that patients who need treatment shouldn’t go undertreated. That’s why we’re using cutting-edge technology to make important medications available in novel formulations. Our vision is to responsibly deliver safe and effective solutions to underserved patients, healthcare providers, and society

780 Dedham Street, Suite 800

Canton, MA 02021

©2016 Collegium Pharmaceutical, Inc. All rights reserved.

Related Videos
Insight on the Promising 52-Week KarXT Data with Rishi Kakar, MD
Sunny Rai, PhD: “I” Language Markers Do Not Detect Depression in Black Individuals
Rebecca A. Andrews, MD: Issues and Steps to Improve MDD Performance Measures
A Voice Detecting Depression? Lindsey Venesky, PhD, Discusses New Data
Daniel Karlin, MD: FDA Grants Breakthrough Designation to MM120 for Anxiety
Peter Lio, MD: Minimizing Painful Pediatric Dermatologic Procedures
Leesha Ellis-Cox: Steps to Closing the Bipolar Disorder Diagnosis Gap for Blacks
© 2024 MJH Life Sciences

All rights reserved.